Last Price
0.023
Today's Change
-0.002 (8.00%)
Day's Change
0.023 - 0.025
Trading Volume
382,123
Market Cap
Shares Outstanding
Avg Volume
Avg Price (50 Days)
Avg Price (200 Days)
PE Ratio
EPS
Earnings Announcement
Previous Close
Open
Day's Range
Year Range
Trading Volume
1 Day Change
5 Day Change
1 Month Change
3 Month Change
6 Month Change
Ytd Change
1 Year Change
3 Year Change
5 Year Change
10 Year Change
Max Change
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.